» Articles » PMID: 11737464

A Critical Evaluation of Current Protocols for the Follow-up of Women Treated for Gynecological Malignancies: a Pilot Study

Overview
Date 2001 Dec 12
PMID 11737464
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

This retrospective review was undertaken to determine the efficacy of routine follow-up in the detection and management of recurrent cancer. The case notes of all women attending a regional cancer center who were diagnosed with cancer in 1997 were reviewed. Of 81 new cancers followed up for a median of 42 months (range 36-48), 14 have recurred after curative treatment and there were six cases of persistent disease. The median number of clinic visits per patient was 3.5 (range 1-16). Eight recurrences (57.1%) were diagnosed at scheduled outpatient appointments, three (2 l.4%) presented to the general practitioner (GP), and three were seen as emergencies in hospital. Seventeen patients with persistent/recurrent disease have died and three are alive with disease. The median time from initial presentation to disease recurrence was 12 months (range 5-25) and the median time from recurrence to death was 5 months (range 1-20). The longest interval between onset of symptoms and diagnosis of recurrence (4 months) occurred in those presenting at scheduled outpatient clinics. This study demonstrates that the current follow-up protocol is associated with delays in diagnosing recurrence, because symptomatic patients postpone seeking help until their scheduled visit. We have therefore commenced a prospective study evaluating other models of follow-up.

Citing Articles

Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.

Zachou G, El-Khouly F, Dilley J Cochrane Database Syst Rev. 2023; 8:CD006119.

PMID: 37650760 PMC: 10471005. DOI: 10.1002/14651858.CD006119.pub4.


'We do need to keep some human touch'-Patient and clinician experiences of ovarian cancer follow-up and the potential for an electronic patient-reported outcome pathway: A qualitative interview study.

Kennedy F, Shearsmith L, Holmes M, Peacock R, Lindner O, Megson M Eur J Cancer Care (Engl). 2022; 31(2):e13557.

PMID: 35146821 PMC: 9287040. DOI: 10.1111/ecc.13557.


Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.

Chao X, Fan J, Song X, You Y, Wu H, Wu M Front Oncol. 2020; 10:591253.

PMID: 33365270 PMC: 7750634. DOI: 10.3389/fonc.2020.591253.


Delphi survey to inform patient-reported symptom monitoring after ovarian cancer treatment.

Shearsmith L, Kennedy F, Lindner O, Velikova G J Patient Rep Outcomes. 2020; 4(1):71.

PMID: 32857244 PMC: 7453693. DOI: 10.1186/s41687-020-00237-2.


How Do We Follow Up Patients With Endometrial Cancer?.

Jeppesen M, Mogensen O, Hansen D, Bergholdt S, Jensen P Curr Oncol Rep. 2019; 21(7):57.

PMID: 31093835 DOI: 10.1007/s11912-019-0805-3.